Yoğun Bakımda İnflamatuar Barsak Hastalıkları

Daniel M. Autenrieth, Daniel C. Baumgart, Toxic Megacolon, Inflammatory Bowel Diseases, Volume 18, Issue 3, 1 March 2012, Pages 584–591, https://doi.org/10.1002/ibd.21847

Lightner AL, Pemberton JH, Dozois EJ, Larson DW, Cima RR, Mathis KL, Pardi DS, Andrew RE, Koltun WA, Sagar P, Hahnloser D. The surgical management of inflammatory bowel disease. Curr Probl Surg. 2017 Apr;54(4):172-250. doi: 10.1067/j.cpsurg.2017.02.006.

https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html

Crockett SD, Hansen RA, Stürmer T, Schectman R, Darter J, Sandler RS, et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2012;18(6):1048-56. DOI: 10.1002/ibd.21822

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. DOI: 10.1056/NEJMoa1215734

Friedman S, Blumberg RS. Inflammatory bowel disease. In: Longo DL, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw Hill; 2012. p. 4961-83.

Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107(12):1879-87. DOI: 10.1038/ajg.2012.333

Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661-73. DOI: 10.1038/ajg.2011.72

Levine JS, Burakoff R. Inflammatory bowel disease: medical considerations. In: Greenberger N, Blumberg R, Burakoff R, editors. Current diagnosis & treatment: gastroenterology, hepatology & endoscopy. 2nd ed. New York: McGraw Hill; 2012. p. 23-35.

Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841-5. DOI: 10.1056/NEJM199406303302601

Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schütz T, et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clin Nutr. 2006;25(2):260-74. DOI: 10.1016/j.clnu.2006.01.007

Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. DOI: 10.3748/wjg.v20.i12.3231.

Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Gastroenterology. 2010;139(6):1846-53. DOI: 10.1111/j.1572-0241.2008.02052.x

Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-28. DOI: 10.1016/S0140-6736(17)30182-4

Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol. 2005;11(16):2371-84. DOI: 10.3748/wjg.v11.i16.2371

Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52(9):2015-21. DOI: 10.1007/s10620-006-9622-2

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. DOI: 10.1056/NEJMoa050516

Sandborn WJ, Su C, Sands BE, D’Haens G, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-36. DOI: 10.1056/NEJMoa1606910

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease: long-term efficacy. Lancet. 2020;395(10239):1237-46. DOI: 10.1056/NEJMoa1602773

Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31(1):307-27. DOI: 10.1016/s0889-8553(01)00019-x

Tezel A. Etiopathogenesis of ulcerative colitis. Turkiye Klinikleri J Gastroenterohepatol-Special Topics. 2009;2(1):7-12.

Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929-36. DOI: 10.1053/j.gastro.2008.01.012

Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-10. DOI: 10.1136/gut.38.6.905

Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-8. DOI: 10.1136/bmj.2.4947.1041

Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2021;15(5):679-98. DOI: 10.1093/ecco-jcc/jjab178

Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):661-5. DOI: 10.1097/00054725-200409000-00026

Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34. DOI: 10.1038/nature06005